Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Based on the existing research results, Osimertinibi is effective not only for patients with
sensitizing EGFR mutations, but also for other less common EGFR mutations. However, no
studies have been done so far regarding the difference in efficacy of various EGFR mutation
subtypes. Meanwhile, the presenting studies data of the safety and efficacy of Osimertinib as
first-line therapy for NSCLC is very limited. Therefore, this study aims at assessing the
safety and efficacy of Osimertinib as First-line therapy for patients with EGFR
mutation-positive locally advanced or Metastatic Non-squamous NSCLC as well as the its
difference in efficacy of various EGFR mutation subtypes.